

2018 ANNUAL MEETING

May 29 – June 1, 2018

Loews Miami Beach Hotel | Miami, Florida



Treatment of Psychiatric Illness Across the Lifespan

Call for Proposals

You are invited to participate in the Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP) to be held at the Loews Miami Beach, May 29 – June 1, 2018, by submitting a proposal and attending the meeting. The committee welcomes submissions from the U.S. as well as international proposals.

The theme of this year's meeting is *“Treatment of Psychiatric Illness Across the Lifespan.”*

The Program Committee is especially interested in proposals on the topics below, but welcomes all submissions.

- a. Treatment of psychiatric disorders across the lifespan, including youth, adolescents, young adult, and geriatric
 - a. Panels/workshops that address specific disorders across the lifespan, including childhood/adolescence, transition to adulthood, adulthood, pregnancy and postpartum, mid-life, and the elderly;
 - b. Panels/workshops that focus on specific times during the lifespan, including childhood/adolescence, ageing, reproductive years; neurodevelopment and risk relevant to period across the lifespan
- b. Primary prevention of psychiatric disorders
- c. Adulthood autism and autism across the lifespan
- d. Medical marijuana
- e. Opiate abuse across the lifespan, including in youth, adults, and the elderly
- f. Career development/changes across the lifespan
- g. Sexuality across the lifespan
- h. Suicide risk and prevention across the lifespan

Detailed instructions to submit your abstracts are available at www.ASCPMeeting.org.

2018 Submission Categories and Deadlines:

<i>Workshops and Panels Overall (Chair) Proposals:</i>	<i>November 6, 2017</i>
<i>Workshops and Panels Individual Presenter Proposals:</i>	<i>November 13, 2017</i>
<i>New Investigator Awards:</i>	<i>January 30, 2018</i>
<i>Posters:</i>	<i>January 30, 2018</i>
<i>Individual Research Reports:</i>	<i>January 30, 2018</i>
Pharmaceutical Pipeline Presentations:	March 12, 2018

The 2018 meeting will again include representatives from academia, the National Institutes of Health (NIH), Food and Drug Administration (FDA), European regulatory agencies and industry to discuss key aspects of neuropsychiatric drug development, including the impact of diagnostic changes and personalized interventions based on biomarkers or genetic information. A Steering Committee chaired by Drs. Marlene Freeman and John Newcomer with representation of the sectors that are part of the ASCP community will lead the direction of the meeting. Representatives from the FDA, EMA, NIMH, NIDA, NIAAA, and academia comprise the 2018 Steering Committee. A Program Committee under the leadership of Drs. Holly Swartz and Anita Clayton will be responsible for review of all program submissions.

Please visit www.ASCPMeeting.org for registration and housing details.

We welcome your participation!